<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572477</url>
  </required_header>
  <id_info>
    <org_study_id>201601675A0</org_study_id>
    <nct_id>NCT04572477</nct_id>
  </id_info>
  <brief_title>The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome</brief_title>
  <official_title>The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyloid plaques and tau protein are the landmarks of neurodegeneration in Alzheimer's disease&#xD;
      (AD). On the other hand, it is reported that cerebral ischemia may induce amyloid plaques and&#xD;
      tau protein accumulation. However, it was difficult to in vivo disentangle the complex and&#xD;
      dynamic interactions between AD pathophysiology and cerebral vascular injury in the&#xD;
      development of post-stroke cognitive impairment in the past. With the advent of novel&#xD;
      radiotracers specific to cerebral amyloid plaques and tau protein, we aim to conduct a&#xD;
      prospective multimodal neuroimaging cohort study to investigate the contribution of vascular&#xD;
      injury, amyloid plaques and tau protein to stroke recovery and post-stroke cognitive&#xD;
      impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Group A (acute stroke/TIA patients), n=200 Group B (chronic stroke/TIA patients), n=200 Group C (healthy elderly controls), n=30</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Imaging positive and negative conditions</measure>
    <time_frame>through study completion, an average of 1.5 year</time_frame>
    <description>PET images are visually assessed by independent raters, who are nuclear medicine doctors and blinded to all clinical and diagnostic information. The raters classify each scan as 0-1 (no significant uptake)、2 (suspicious uptake)、3-4 (significant uptake). The score &gt;= 2 is deemed as positive condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chi-square test will be performed to analyze dementia conversion rate.</measure>
    <time_frame>through study completion, an average of 1.5 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Post-stroke Dementia, Vascular Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>[18F]THK-5351</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.&#xD;
Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.&#xD;
B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.&#xD;
C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>[18F]AV-45</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary endpoint A. To compare the distribution of cerebral amyloid plaques and tau protein between stroke patients and normal controls.&#xD;
Secondary endpoints A. To compare tau distribution on [18F]THK5351 PET at acute, subacute and chronic stroke stages.&#xD;
B. To correlate the [18F]THK5351 PET findings with [18F]AV45 PET, brain MRI, and functional and cognitive performance.&#xD;
C. To compare the [18F]THK5351PET, [18F]AV45 PET, and brain MRI findings among stroke patients with no cognitive impairment (NCI), storke patients with VaMCI and stroke patients with PSD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]THK-5351</intervention_name>
    <description>F-18 THK PET Imaging</description>
    <arm_group_label>[18F]AV-45</arm_group_label>
    <arm_group_label>[18F]THK-5351</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]AV-45</intervention_name>
    <description>F-18 AV45 PET Imaging</description>
    <arm_group_label>[18F]AV-45</arm_group_label>
    <arm_group_label>[18F]THK-5351</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Inclusion criteria for acute stroke/TIA patients (Group A, n=200)&#xD;
&#xD;
               -  Males or females with age &gt;= 50 years old&#xD;
&#xD;
               -  Having acute cerebral stroke or transient ischemic attack in recent 1 month&#xD;
&#xD;
               -  Female subjects of childbearing potential must practice effective contraception&#xD;
                  during the study and be willing and able to continue contraception after the&#xD;
                  final study&#xD;
&#xD;
               -  Provision of signed informed consent&#xD;
&#xD;
          2. Inclusion criteria for chronic stroke/TIA patients (Group B, n=200)&#xD;
&#xD;
               -  Males or females with age &gt;= 50 years old&#xD;
&#xD;
               -  Having cerebral stroke or transient ischemic attack in the past 1.5 years&#xD;
&#xD;
               -  Having had tau PET imaging study within 1 year after the index stroke/TIA event&#xD;
&#xD;
               -  Female subjects of childbearing potential must practice effective contraception&#xD;
                  during the study and be willing and able to continue contraception after the&#xD;
                  final study&#xD;
&#xD;
               -  Provision of signed informed consent&#xD;
&#xD;
          3. Inclusion criteria for healthy elderly controls (Group C, n=30)&#xD;
&#xD;
               -  Males or females with age &gt;= 50 years old&#xD;
&#xD;
               -  Without history of cerebral stroke or transient ischemic attack&#xD;
&#xD;
               -  Ability to participate in cognitive and neuroimaging assessments&#xD;
&#xD;
               -  Female subjects of childbearing potential must practice effective contraception&#xD;
                  during the study and be willing and able to continue contraception after the&#xD;
                  final study&#xD;
&#xD;
               -  Provision of signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria for all subjects&#xD;
&#xD;
          -  Presence of dementia diagnosis before the index stroke or at the initial screening&#xD;
&#xD;
          -  History of vascular MCI (VaMCI)&#xD;
&#xD;
          -  The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly&#xD;
             (IQCODE) score &gt;=104 at the initial screening 47.&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values.&#xD;
&#xD;
          -  Clinically significant or unstable medical or psychiatric illness.&#xD;
&#xD;
          -  Epilepsy history.&#xD;
&#xD;
          -  Cognitive impairment resulting from trauma or brain damage.&#xD;
&#xD;
          -  Substance abuse or alcoholism in the past 3 months.&#xD;
&#xD;
          -  General MRI, and / or PET exclusion criteria.&#xD;
&#xD;
          -  Pregnant or becoming pregnant during the study (as documented by pregnancy testing at&#xD;
             screening or at any date during the study according to the PI discretion) or current&#xD;
             breast feeding.&#xD;
&#xD;
          -  History of allergy to 18F-labelled radionucleic agents, [18F]AV45 or [18F]THK5351.&#xD;
&#xD;
          -  Subjects having high risks for the study according to the PI discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huang Kuo-Lun, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Stroke Section, Department of Neurology, Chang-Gung memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huang Kuo-Lun, M.D.</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8340</phone_ext>
    <email>drkuolun@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chen Jing-Fang</last_name>
    <phone>+886-3-3281200</phone>
    <phone_ext>8413</phone_ext>
    <email>tp6tp6fg@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, Chang-Gung memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <state>Guishan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huang Kuo-Lun, M.D.</last_name>
      <phone>+886-3-3281200</phone>
      <phone_ext>8340</phone_ext>
      <email>drkuolun@cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 3, 2021</last_update_submitted>
  <last_update_submitted_qc>October 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

